UNSPSC 51321816: Cetaben

This classification denotes an anti-lipidemic agent with the molecular formula C23H39NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, DTL5W0113X chemically known as benzoic acid, 4-(hexadecylamino)- but generally known as cetaben, which bears US NIH Compound Identifier 47263. European Medicines Agency schedules Cetaben in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07444MIG.

The term CETABEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18). Most nations schedule cetaben under HS 29224995 and SITC 51465. As of Q4 2014, CETABEN remains the US FDA Preferred Term for this commodity. Cetaben bears US NLM identifiers UMLS ID C0055140 and NCI Concept Code C73814. SMILES: OC(=O)C1CCC(NCCCCCCCCCCCCCCCC)CC1.

UNSPSC 51321816 Cetaben is a Commodity code under which state and local governments procure emergency medical pharmaceuticals and specialty medications for fire rescue, emergency medical services, and public health programs. Recent solicitations show state and local buyers acquiring specific advanced life support drugs — epinephrine, labetalol, adenosine, diltiazem — in measured quantities with strict expiration-date and shelf-life controls, as well as generic multi-source pharmaceuticals distributed through cooperative purchasing platforms serving multiple state and local health facilities. The issuing bodies span fire departments (Tampa Fire Rescue in Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local participants including Oregon). Most recent activity clusters around emergency medical supply contracts and cooperative pharmaceutical procurement vehicles rather than single-jurisdiction buys.

Geographic activity centers on Florida, Texas, and Minnesota through the MMCAP platform. The City of Tampa's Purchasing Department issued IFB No. 26P00188 for Advanced Life Support Medications on April 24, 2026, with a due date of April 8, 2026 and estimated contract value of $40,000.00, requiring delivery within ten calendar days with a one-year base term and optional two additional one-year renewals plus three unilateral 30-day extensions; the solicitation carries a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount capped at $10,000. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, to establish multiple generic pharmaceutical and OTC contracts for authorized wholesalers with awards effective July 1, 2026 and a two-year initial term; price competitiveness weighted at 75 percent of evaluation. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a proposed Direct-to-Manufacturer Prescriptions program but made no award or funding commitments at the RFI stage.